

SWOG S2414: A randomized phase III trial incorporating pathologic response in participants with early-stage NSCLC to optimize immunotherapy in the adjuvant setting (INSIGHT)

BACKGROUND


- Neoadjuvant chemo-immunotherapy is now a SOC for early-stage NSCLC
- Benefit of post-operative IO uncertain after pathCR

Primary Endpoint:

- Compare DFS between arms

Key Secondary Endpoints: Compare

- OS
- Toxicities
- EFS



PRAGMATIC FEATURES

- **Any** FDA approved neoadjuvant chemo + IO permitted
- **Local** pathCR review
- Nodal evaluation intensity **recommended**, but **not** mandated
- Enrollment **up to 12 weeks post-op**
- Sister study (EA5231) available if non-pathCR, so **all patients covered**
- **ECOG 0-2**

PI: Jeremy Cetnar, MD

Co-PI: Ray Osarogiagbon, MD

Stats Lead: Yingqi Zhao, PhD

SWOG Lung Chair: Jhanelle Gray, MD

* Local pathology review

** If non-PCR (no pathologic complete response), consider for EA5231